Inter J Stomatol ›› 2018, Vol. 45 ›› Issue (3): 351-357.doi: 10.7518/gjkq.2018.03.020
• Reviews • Previous Articles Next Articles
Ji Ning, Zhao Hang, Zeng Xin, Chen Qianming
CLC Number:
| [1] Dreyfus DH.Herpesviruses and the microbiome[J]. J Allergy Clin Immunol, 2013, 132(6):1278-1286. [2] Suazo PA, Ibañez FJ, Retamal-Díaz AR, et al.Evasion of early antiviral responses by herpes simplex viruses[J]. Mediators Inflamm, 2015, 2015:593757. [3] Galdiero S, Falanga A, Tarallo R, et al.Peptide inhi-bitors against herpes simplex virus infections[J]. J Pept Sci, 2013, 19(3):148-158. [4] Zis P, Stritsou P, Angelidakis P, et al.Herpes simplex virus type 2 encephalitis as a cause of ischemic stroke: case report and systematic review of the literature[J]. J Stroke Cerebrovasc Dis, 2016, 25(2):335-339. [5] Conrady CD, Drevets DA, Carr DJ.Herpes simplex type Ⅰ (HSV-1) infection of the nervous system: is an immune response a good thing[J]. J Neuroimmu-nol, 2010, 220(1/2):1-9. [6] Harris SA, Harris EA.Herpes simplex virus type 1 and other pathogens are key causative factors in sporadic Alzheimer’s disease[J]. J Alzheimers Dis, 2015, 48(2):319-353. [7] Zarrouk K, Piret J, Boivin G.Herpesvirus DNA poly-merases: structures, functions and inhibitors[J]. Virus Res, 2017, 234:177-192. [8] De Clercq E.Antivirals: past, present and future[J]. Biochem Pharmacol, 2013, 85(6):727-744. [9] De Clercq E, Holý A.Acyclic nucleoside phospho-nates: a key class of antiviral drugs[J]. Nat Rev Drug Discov, 2005, 4(11):928-940. [10] De Clercq E.The discovery of antiviral agents: ten different compounds, ten different stories[J]. Med Res Rev, 2008, 28(6):929-953. [11] Jiang YC, Feng H, Lin YC, et al.New strategies against drug resistance to herpes simplex virus[J]. Int J Oral Sci, 2016, 8(1):1-6. [12] Hornig J, McGregor A. Design and development of antivirals and intervention strategies against human herpesviruses using high-throughput approach[J]. Expert Opin Drug Discov, 2014, 9(8):891-915. [13] Whitley RJ, Roizman B.Herpes simplex virus infec-tions[J]. Lancet, 2001, 357(9267):1513-1518. [14] Gilbert C, Bestman-Smith J, Boivin G.Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms[J]. Drug Resist Updat, 2002, 5(2):88-114. [15] Prusoff WH.Synthesis and biological activities of iododeoxyuridine, an analog of thymidine[J]. Biochim Biophys Acta, 1959, 32(1):295-296. [16] De Clercq E.Chapter 1 Looking back in 2009 at the dawning of antiviral therapy now 50 years ago[J]. Adv Virus Res, 2009, 73:1-53. [17] Kaufman HE.Clinical cure of herpes simplex kera-titis by 5-iodo-2-deoxyuridine[J]. Proc Soc Exp Biol Med, 1962, 109:251-252. [18] Kaufman HE, Heidelberger C.Therapeutic antiviral action of 5-trifluoromethyl-2’-deoxyuridine in herpes simplex keratitis[J]. Sci, 1964, 145(3632):585-586. [19] Whitley RJ, Ch’ien LT, Dolin R, et al.Adenine arab-inoside therapy of herpes zoster in the immunosup-pressed. NIAID collaborative antiviral study[J]. N Engl J Med, 1976, 294(22):1193-1199. [20] Whitley RJ, Soong SJ, Dolin R, et al.Adenine arab-inoside therapy of biopsy-proved herpes simplex en-cephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study[J]. N Engl J Med, 1977, 297(6):289-294. [21] Whitley R, Arvin A, Prober C, et al.A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection[J]. N Engl J Med, 1991, 324(7):444-449. [22] Elion GB, Furman PA, Fyfe JA, et al.Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine[J]. Proc Natl Acad Sci USA, 1977, 74(12):5716-5720. [23] Schaeffer HJ, Beauchamp L, de Miranda P, et al. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group[J]. Nature, 1978, 272(5654):583-585. [24] Erice A, Chou S, Biron KK, et al.Progressive disease due to ganciclovir-resistant cytomegalovirus in im-munocompromised patients[J]. N Engl J Med, 1989, 320(5):289-293. [25] Gnann JW Jr, Crumpacker CS, Lalezari JP, et al.Sori-vudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-in-fected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster Study Group[J]. Antimicrob Agents Chemother, 1998, 42(5):1139-1145. [26] Perry CM, Faulds D.Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections[J]. Drugs, 1996, 52(5):754-772. [27] Haynes P, Lambert TR, Mitchell ID.Comparative [28] Perry CM, Wagstaff AJ.Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections[J]. Drugs, 1995, 50(2):396-415. [29] Field HJ, Tewari D, Sutton D, et al.Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosup-pression model[J]. Antimicrob Agents Chemother, 1995, 39(5):1114-1119. [30] Lea AP, Bryson HM.Cidofovir[J]. Drugs, 1996, 52(2):225-231. [31] Ciancio G, Burke GW, Mattiazzi A, et al.Cytomega-lovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation[J]. Clin Transplant, 2004, 18(4):402-406. [32] Boivin G, Goyette N, Gilbert C, et al.Absence of cytomegalovirus-resistance mutations after valganci-clovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients[J]. J Infect Dis, 2004, 189(9):1615-1618. [33] Deeks SG, Collier A, Lalezari J, et al.The safety and efficacy of adefovir dipivoxil, a novel anti-human im-munodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial[J]. J Infect Dis, 1997, 176(6):1517-1523. [34] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B[J]. N Engl J Med, 2003, 348(9):800-807. [35] Ramsay ID, Attwood C, Irish D, et al.Disseminated adenovirus infection after allogeneic stem cell trans-plant and the potential role of brincidofovir-Case series and 10 year experience of management in an adult transplant cohort[J]. J Clin Virol, 2017, 96:73-79. [36] Lederman ER, Davidson W, Groff HL, et al.Progre-ssive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001[J]. J Infect Dis, 2012, 206(9):1372-1385. [37] Toth K, Tollefson AE, Spencer JF, et al.Combina-tion therapy with brincidofovir and valganciclovir against species C adenovirus infection in the immunosu-ppressed Syrian hamster model allows for substantial reduction of dose for both compounds[J]. Antiviral Res, 2017, 146:121-129. [38] Quenelle DC, Kern ER.Treatment of vaccinia and cowpox virus infections in mice with CMX001 and ST-246[J]. Viruses, 2010, 2(12):2681-2695. [39] De Clercq E.Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo-[2,3-d]pyrimidine nucleoside analogues[J]. Med Res Rev, 2003, 23(3):253-274. [40] De Clercq E.Selective anti-herpesvirus agents[J]. Antivir Chem Chemother, 2013, 23(3):93-101. [41] Migliore M.FV-100: the most potent and selective anti-varicella zoster virus agent reported to date[J]. Antivir Chem Chemother, 2010, 20(3):107-115. [42] Pentikis HS, Matson M, Atiee G, et al.Pharmacoki-netics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers[J]. Antimicrob Agents Chemother, 2011, 55(6):2847-2854. [43] Andrei G, Snoeck R.Advances in the treatment of varicella-zoster virus infections[J]. Antiviral Agents, 2013, 67:107-168. [44] Krecmerova M.Amino acid ester prodrugs of nucleo-side and nucleotide antivirals[J]. Mini Rev Med Chem, 2017, 17(10):818-833. [45] De SK, Hart JC, Breuer J.Herpes simplex virus and varicella zoster virus: recent advances in therapy[J]. Curr Opin Infect Dis, 2015, 28(6):589-595. [46] Tyring SK, Plunkett S, Scribner AR, et al.Valoma-ciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a rando-mized, double-blind, active-controlled trial[J]. J Med Virol, 2012, 84(8):1224-1232. [47] Price NB, Prichard MN.Progress in the development of new therapies for herpesvirus infections[J]. Curr Opin Virol, 2011, 1(6):548-554. [48] Houldcroft CJ, Bryant JM, Depledge DP, et al.Detec-tion of low frequency multi-drug resistance and novel putative maribavir resistance in immunocompromised pediatric patients with cytomegalovirus[J]. Front Mic-robiol, 2016, 7:1317. [49] Bright PD, Gompels M, Donati M, et al.Successful oral treatment of Ganciclovir resistant cytomegalo-virus with Maribavir in the context of primary immuno-deficiency: first case report and review[J]. J Clin Virol, 2017, 87:12-16. |
| [1] | Yu Lerong,Li Xiangwei,Ai Hong. Research progress on the stemness maintenance of dental pulp stem cells [J]. Int J Stomatol, 2023, 50(4): 463-471. |
| [2] | Wang Jingyan,Qin Man,Wang Xin.. Research progress on the clinical characteristics of Axenfeld-Rieger syndrome and the pathogenic mechanisms of paired-like homeodomain transcription factor 2 mutations [J]. Int J Stomatol, 2023, 50(2): 224-229. |
| [3] | Gong Tao,Li Yuqing,Zhou Xuedong.. Research progress on sugar transporter and regulatory mechanisms in Streptococcus mutans [J]. Int J Stomatol, 2022, 49(5): 506-510. |
| [4] | Zhao Manzhu,Song Jinlin. Research progress on expression distribution and regulation mechanism of clock genes in tooth development [J]. Int J Stomatol, 2022, 49(4): 380-385. |
| [5] | Li Junlin,Xiao Liwei. Research progress on the mechanism and efficacy of molar distalization with clear aligner technique [J]. Int J Stomatol, 2022, 49(1): 109-115. |
| [6] | Yang Peipei,Yang Yuchen,Zhang Qiang. Advances in the mechanism and effect of nicotine on alveolar osteoclasts [J]. Int J Stomatol, 2020, 47(5): 616-620. |
| [7] | Liu Lin,Zhou Jieyu,Wu Yafei,Zhao Lei. Application of probiotic ecological regulation in prevention and treatment of periodontal diseases [J]. Int J Stomatol, 2020, 47(2): 131-137. |
| [8] | Huang Xiaoyu,Li Mingyun,Zhou Xue- dong,Cheng Lei. Effects of systemic and local factors on microbial homeostasis around implants [J]. Int J Stomatol, 2019, 46(6): 730-734. |
| [9] | Hao Fu,Sun Rui. Research progress on second primary carcinoma of head and neck squamous cell carcinoma [J]. Int J Stomatol, 2019, 46(5): 585-592. |
| [10] | Liu Dan, Ren Biao, Cheng Lei.. Research development of silver nanoparticle on prevention and treatment of oral infectious disease [J]. Inter J Stomatol, 2018, 45(4): 408-413. |
| [11] | Liu Caiyun, Tao Yiran. Correlation between taste injury and diabetes [J]. Inter J Stomatol, 2018, 45(3): 358-361. |
| [12] | Zheng Zhi, Yan Shiguo. Relationship between herpes virus and periodontitis [J]. Inter J Stomatol, 2018, 45(2): 224-227. |
| [13] | Wang Maoxia, Dai Guanyu, Meng Yukun. Mechanism of vertical food impaction [J]. Inter J Stomatol, 2018, 45(2): 245-248. |
| [14] | Wang Zhiqiang, Ma Lijuan, Zhou Haijing, Yang Lan, Nie Hongbing, Xue Long. Research progress on antitumor effect and mechanism of probiotics [J]. Inter J Stomatol, 2017, 44(6): 636-641. |
| [15] | Tang Qiuling, Li Gege, Pan Jiahui, Hou Yubo, Meng Yang, Yu Weixian.. Mechanism of pyroptosis and Porphyromonas gingivalis in periodontitis development process [J]. Inter J Stomatol, 2017, 44(6): 660-663. |